Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613991 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL8613997 | 0.86 | ALDH1A1 (0.51) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL8723683 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL12006800 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| Butane SCHEMBL11744413 | 0.81 | MAOB (0.49) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL77922 | 0.81 | ALDH1A1 (0.62) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL23091898 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL291637 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL261866 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB | |
| SCHEMBL22590899 | 0.78 | ALDH1A1 (0.58) | ALDH1A1TSHRHTTHPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5851724-A | Method for producing lithographic plates with imaging elements comprising a photosensitive acid precursor | AGFA-GEVAERT, N.V. (BE) | 1998-12-22 | — | — | US | claimed |
| EP-0701173-B1 | Method for producing lithographic plates with imaging elements comprising a photosensitive acid precusor | AGFA GEVAERT NV (BE) | 1997-11-12 | — | — | EP | claimed |
| EP-0701173-A1 | Method for producing lithographic plates with imaging elements comprising a photosensitive acid precusor | AGFA-GEVAERT N.V. (BE) | 1996-03-13 | — | — | EP | claimed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | ALDH1A1 125/4885TSHR 3238/4885HTT 2772/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | ALDH1A1 1136/4885TSHR 1823/4885HTT 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.